AKT inhibitor capivasertib reverses EVI1‐driven resistance to venetoclax in acute myeloid leukaemia
- 4 June 2026
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 84-95
Abstract
Summary: Acute myeloid leukaemia (AML) with MDS1 and EVI1 complex locus ( MECOM ) rearrangement is recognized by the World Health Organization as a distinct entity characterized by poor prognosis and aggressive disease progression. This rearrangement evokes aberrant ecotropic viral integration site 1 ( EVI1 ) overexpression, which enhances leukaemic stem cell self‐renewal and drives chemoresistance. However, the mechanisms by which EVI1 contributes to venetoclax resistance remain unclear. In this study, patients with AML were stratified into the EVI1 ‐high and EVI1 ‐low groups based on transcript levels. The EVI1 ‐high subgroup exhibited significantly inferior clinical outcomes and reduced complete remission rates following chemotherapy or venetoclax‐based regimens. Meanwhile, we demonstrated that elevated EVI1 expression confers resistance to venetoclax by stabilizing myeloid cell leukaemia 1 (MCL‐1) through activation of the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (AKT) signalling pathway in vitro. Mechanistically, elevated EVI1 levels were associated with increased phosphorylation of MCL‐1 at threonine 163 (T163pMCL‐1), thereby stabilizing MCL‐1 by attenuating its ubiquitin–proteasome‐mediated degradation. Importantly, cotreatment with venetoclax and the clinically available AKT inhibitor capivasertib effectively restored sensitivity in both cell lines and patient‐derived primary AML samples with high EVI1 expression. Overall, our findings reveal a novel molecular mechanism underlying EVI1‐mediated venetoclax resistance through PI3K/AKT‐driven MCL‐1 stabilization and suggest a combination strategy involving AKT inhibition as a promising approach for overcoming therapeutic resistance in this high‐risk AML subset.Keywords
Funding Information
- National Natural Science Foundation of China (82570217)
This publication has 55 references indexed in Scilit:
- Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphomaLeukemia, 2024
- Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysisHematological Oncology, 2024
- Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid LeukemiaAdvanced Science, 2023
- AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axisCellular Oncology, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2022
- High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AMLLeukemia, 2015
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cellsLeukemia, 2012
- Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcriptionOncogene, 2012